Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate
• Androgen-independent disease
• * Testosterone ≤ 50 ng/mL
• * Is currently receiving luteinizing hormone-releasing hormone agonists as maintenance or has undergone prior orchiectomy for testosterone suppression
• Progressive disease, as defined by ≥ 1 of the following:
• * Clinical or radiographic evidence of metastases that have progressed irrespective of PSA changes
• * Asymptomatic (non-opioid requiring) bone-only metastatic disease with a rising PSA on separate measurements ≥ 1 week apart
• * No symptomatic bone metastases
• * Biochemical progression (PSA-only disease), defined as having an absolute PSA value of ≥ 2.0 ng/mL on 3 separate measurements ≥ 2 weeks apart with a PSA doubling time of ≤ 10 months
• No evidence of CNS (brain or leptomeningeal) metastases or pleural and/or pericardial effusions
• PATIENT CHARACTERISTICS:
• ECOG performance status of 0-1
• ANC ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Serum creatinine ≤ 2.0 mg/dL
• AST \< 3 times normal
• Bilirubin \< 1.5 mg/dL
• PT and PTT normal
• Calcium normal
• Fertile patients must use effective contraception during and for ≥ 28 days after completion of study therapy
• Agrees to abstain from donating blood, semen, or sperm during and for ≥ 28 days after completion of study therapy
• No pre-existing peripheral neuropathy \> grade 1
• No active unresolved infection
• No known contraindication to lenalidomide or sargramostim
• No other malignancies within the past 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or stage Ta transitional cell carcinoma of the bladder
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior chemotherapy for metastatic prostate cancer
• More than 1 year since prior adjuvant and/or neoadjuvant therapy
• More than 4 weeks since prior flutamide (6 weeks for other antiandrogens)
• No prior thalidomide or lenalidomide
• At least 4 weeks since prior surgery or external-beam radiotherapy and recovered
• At least 6 weeks since prior radiopharmaceutical therapy, including samarium-153 or strontium-89, and recovered
• No initiation of bisphosphonate therapy within 1 month before and during study therapy
• * Patients on stable doses of bisphosphonates who show subsequent tumor progression may continue to receive bisphosphonates
• Concurrent daily aspirin for the prevention of thrombotic events required
• * Patients intolerant to aspirin may receive low-dose warfarin as prophylaxis
• No other concurrent investigational agents
• No other concurrent anticancer therapy, including radiotherapy or thalidomide